Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

Author's Avatar
Mar 22, 2023

- SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS -